Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
01
10
2021
accepted:
17
02
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
12
5
2022
Statut:
epublish
Résumé
Multiple sclerosis (MS) is an autoimmune disease confined in the CNS, and its course is frequently subtle and variable. Therefore, predictive biomarkers are needed. In this scenario, we conducted a systematic review and meta-analysis to evaluate the reliability of chitinase 3-like 1 as a biomarker of MS. Research through the main scientific databases (PubMed, Scopus, Web of Science, and Cochrane Library) published from January 2010 to December 2020 was performed using the following keywords: "chitinase 3-like 1 and multiple sclerosis" and "YKL40 and multiple sclerosis." Articles were selected according to the 2020 updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines by 2 authors independently, and data were extracted; 20 of the 90 studies screened were included in the meta-analysis. The main efficacy measure was represented by the standardized mean difference of CSF and blood CHI3L1 levels; Review Manager version 5.4 and R software applications were used for analysis. Higher levels of CHI3L1 were found in CSF of 673 patients with MS compared with 336 healthy controls (size-weighted mean difference [SMD] 50.88; 95% CI = 44.98-56.79; CSF levels of CHI3L1 have a strong correlation with the MS pathologic course, in particular with the mechanism of progression of the disease; it helps to distinguish the PPMS from the RRMS. The potential role of CHI3L1 in serum needs to be further studied in the future.
Sections du résumé
BACKGROUND AND OBJECTIVES
Multiple sclerosis (MS) is an autoimmune disease confined in the CNS, and its course is frequently subtle and variable. Therefore, predictive biomarkers are needed. In this scenario, we conducted a systematic review and meta-analysis to evaluate the reliability of chitinase 3-like 1 as a biomarker of MS.
METHODS
Research through the main scientific databases (PubMed, Scopus, Web of Science, and Cochrane Library) published from January 2010 to December 2020 was performed using the following keywords: "chitinase 3-like 1 and multiple sclerosis" and "YKL40 and multiple sclerosis." Articles were selected according to the 2020 updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines by 2 authors independently, and data were extracted; 20 of the 90 studies screened were included in the meta-analysis. The main efficacy measure was represented by the standardized mean difference of CSF and blood CHI3L1 levels; Review Manager version 5.4 and R software applications were used for analysis.
RESULTS
Higher levels of CHI3L1 were found in CSF of 673 patients with MS compared with 336 healthy controls (size-weighted mean difference [SMD] 50.88; 95% CI = 44.98-56.79;
DISCUSSION
CSF levels of CHI3L1 have a strong correlation with the MS pathologic course, in particular with the mechanism of progression of the disease; it helps to distinguish the PPMS from the RRMS. The potential role of CHI3L1 in serum needs to be further studied in the future.
Identifiants
pubmed: 35534236
pii: 9/4/e1164
doi: 10.1212/NXI.0000000000001164
pmc: PMC9128043
pii:
doi:
Substances chimiques
Biomarkers
0
CHI3L1 protein, human
0
Chitinase-3-Like Protein 1
0
Chitinases
EC 3.2.1.14
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Neurol Neuroimmunol Neuroinflamm. 2020 Nov 10;8(1):
pubmed: 33172960
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Clin Microbiol Infect. 2014 Feb;20(2):123-9
pubmed: 24320992
J Neuroinflammation. 2018 Apr 19;15(1):114
pubmed: 29673365
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
Biomedicines. 2020 Aug 28;8(9):
pubmed: 32872144
Brain. 2010 Apr;133(Pt 4):1082-93
pubmed: 20237129
Front Neurol. 2019 Sep 23;10:1008
pubmed: 31608004
Mult Scler. 2019 Oct;25(11):1444-1451
pubmed: 30113249
J Proteome Res. 2013 Mar 1;12(3):1101-7
pubmed: 23339689
Mult Scler. 2015 Apr;21(5):550-61
pubmed: 25732842
Mult Scler. 2019 Jun;25(7):937-946
pubmed: 29775134
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Mult Scler. 2017 Nov;23(13):1727-1735
pubmed: 28831853
J Neurol. 2005 Sep;252(9):1067-73
pubmed: 15789126
Brain. 2015 Apr;138(Pt 4):918-31
pubmed: 25688078
Sci Rep. 2017 Oct 30;7(1):14293
pubmed: 29084979
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
J Neuroimmunol. 2016 Oct 15;299:112-117
pubmed: 27725108
Stat Med. 2002 Sep 30;21(18):2641-52
pubmed: 12228882
J Neurotrauma. 2010 Jul;27(7):1215-23
pubmed: 20486806
Pharmacol Ther. 2019 Nov;203:107394
pubmed: 31356910
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
Eur J Neurol. 2017 May;24(5):703-712
pubmed: 28261960
Front Neurol. 2020 Dec 08;11:607766
pubmed: 33363512
J Neuroinflammation. 2019 Dec 23;16(1):272
pubmed: 31870389
Am J Pathol. 2008 Jul;173(1):130-43
pubmed: 18556781
PLoS One. 2013 Oct 08;8(10):e77163
pubmed: 24116216
Mult Scler. 2017 Jan;23(1):62-71
pubmed: 27003946
Sci Rep. 2020 Apr 28;10(1):7118
pubmed: 32346016
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Aging Dis. 2019 Jun 01;10(3):664-675
pubmed: 31165009
Psychol Methods. 2006 Jun;11(2):193-206
pubmed: 16784338
Mult Scler Relat Disord. 2021 Jun;51:102870
pubmed: 33819724
Front Immunol. 2019 Jan 10;9:3116
pubmed: 30687321
Nat Rev Neurol. 2020 Sep;16(9):463-464
pubmed: 32555516
Ann Rheum Dis. 2000 Jul;59(7):544-8
pubmed: 10873965
PLoS One. 2020 May 21;15(5):e0233519
pubmed: 32437412
Mult Scler Relat Disord. 2019 Oct;35:176-181
pubmed: 31394405
Mult Scler. 2013 Mar;19(3):268-9
pubmed: 23426170
J Neuroinflammation. 2017 Jun 9;14(1):118
pubmed: 28599675
J Neuroinflammation. 2010 Jun 11;7:34
pubmed: 20540736
J Clin Invest. 2021 Aug 16;131(16):
pubmed: 34228644
Mult Scler. 2019 Apr;25(5):669-677
pubmed: 29564952
Cold Spring Harb Perspect Med. 2019 Mar 1;9(3):
pubmed: 29500303
J Neuroimmunol. 2016 Mar 15;292:52-7
pubmed: 26943959
Brain Pathol. 2012 Jul;22(4):530-46
pubmed: 22074331
Mult Scler. 2011 May;17(5):521-31
pubmed: 21159721